- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03411590
The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers (GaGA)
It is well known than an important part of Nigerian children from the lower social economic class have nutrient deficiencies. Fortified products, such as growing up milks (GUM), may play an important role in reducing the risk and incidence of nutrient deficiencies. However, affordability of GUM is an issue.
In this project the effects are studied of different daily intakes of GUM on iron status, growth, several other nutrient status parameters in blood and urine, cognitive development, and the intestinal microbiome in Nigerian toddlers 1-3 years of age.
The project is a collaboration with the department of Paediatrics and Child health of the Lagos State University College of Medicine in Lagos. The design is based on a three-arm, open (partly blind: statistics, biochemical analyses), randomized intervention trial. Recruitment will take place in Ijora-Badia community in Apapa-Iganmu Local Council Development Area (LCDA) in Lagos. The three groups will be given a multi-micronutrient fortified growing-up milk (PEAK), in amounts of 200, 400 or 600 ml per day during a period of 6 months. Primary objective of this study is to reduce iron deficiency anemia. Based on this objective, in total 150 children have to be included in this study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The present study will be a three-arm, open (partly blind) blind, randomized intervention trial in Nigerian children (12-36 months of age). Recruitment will take place in Ijora-Badia community in Apapa-Iganmu Local Council Development Area (LCDA), Lagos, South-West Nigeria. Ijora-Badia community has the highest burden of under-nutrition; In addition, it consists predominantly of low to middle socioeconomic status population, which is nationally representative, thus making it an ideal choice for this study. All families that are permanent residents of Ijora-Badia and have children aged 12-36 months will be invited to participate in the study. Before screening and recruitment will take place, parents or legal guardians of all potential candidates (toddlers) will be fully informed about the study, requirements and procedures. This means that at the day of screening, recruitment and enrolment, 10-20 children per day, fulfilling inclusion criteria, will be directly assigned to one of the three study groups when a written informed consent is obtained from the parents or legal guardians.
At the day of screening and recruitment, mothers will be required to bring their child to the clinic. At this initial screening toddlers will be evaluated to assess their eligibility for participation to the study according to the inclusion and exclusion criteria (i.e. anthropometric measurements, blood collection for the assessment of haemoglobin levels and information collected by parents). Those toddlers meeting all inclusion criteria will be considered as eligible and will be randomised to one of the three study groups. Prior to the initiation of the intervention, all eligible study participants will be dewormed (medicine, brand, dosage). Baseline measurements will take place that same day, and after 6 months of intervention: anthropometric measurement, a cognitive test (30 minutes), and venous blood sampling (8 ml). For food and nutrient intake indices, and faecal sampling, a proper planning will be made, to be sure that it takes place within 3 days following baseline measurements.
The three groups will be given a multi-micronutrient fortified growing-up milk, in amounts of 200, 400 or 600 ml per day. In case of 400 and 600 ml, the portions (200 ml each) will be spread during the day. Airtight packed portions of milk powder sachets will be delivered weekly at the families by field monitors who also provide instructions for use as well as collect empty sachets for a compliance check. Consumption of test product will start as soon as all baseline examinations and samples have been completed and collected, and will last for 6 months.
Prior to the initiation of the screening and recruitment phase, the study protocol will have to be approved by the Lagos State University Teaching Hospital Research/Ethics Committee, and has to be registered in an acknowledged trial register.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Adedotun J Owolabi, MSc
- Phone Number: 2661 +23401271500
- Email: adedotun.owolabi@frieslandcampina.com
Study Contact Backup
- Name: Anne Schaafsma, PhD
- Phone Number: +34582992424
- Email: anne.schafsma@frieslandcampina.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Normal term birth (caesarean section excluded)
- Boys and girls in the age range of 12 to 36 months at enrolment
- Apparently healthy at screening (assessed with the use of a medical history record)
- Hb ≥70 g/L and ≤109 g/L, according to WHO guidelines 27
- Mild to moderate acute malnutrition (i.e. HAZ, WAZ <-1 SD and > -3 SD)
- Parents and/or legal guardians are residents of Oshodi LGA
- Parents and/or legal guardians do not plan to migrate during the study
- Written informed consent from parents and/or legal guardians
- Children able to consume a maximum of 96g (= 600 ml) of product per day
Exclusion Criteria:
- Severe anaemia (Hb<70 g/L) or normal Hb (Hb≥110 g/L)
- Severe acute malnutrition (HAZ, WAZ <-3 SD) requiring hospitalization
- Chronic or severe illness requiring hospitalisation and/or special treatment
- Recent medical history (past 3 months) of serious infections, injuries and/or surgeries
- Any known allergies or intolerances to milk or milk ingredients
- Predominantly breast-fed infants or toddlers
- Consumption of any other fortified foods or supplements
- Participation to other micronutrient supplementation programmes
- Participation to any other nutritional study in the last 6 months
- Participation to another clinical study or receipt of an investigational drug in the last 30 days
- Indication that they are likely to move within the period of study intervention
- Family members of employees of the Sponsor or the study site.
- Use of any prescription medications prior to and/or during the study period for more than or equal to two weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 200ml
Toddlers will be allocated to the 200 ml group
|
Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk.
The intervention period will last for 6 months.
For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
|
Other: 400ml
Toddlers will be allocated to the 400 ml group
|
Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk.
The intervention period will last for 6 months.
For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
|
Other: 600ml
Toddlers will be allocated to the 600 ml
|
Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk.
The intervention period will last for 6 months.
For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Iron deficiency anaemia
Time Frame: 6 Months
|
Prevalence of Iron deficiency anaemia as assessed by haemoglobin concentration
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematocrit
Time Frame: 6 months
|
Hematocrit to substantiate the effect of iron supplementation on Hb
|
6 months
|
Ferritin
Time Frame: 6 months
|
ferritin to substantiate the effect of iron supplementation on Hb concentration
|
6 months
|
plasma concentrations of specific inflammation markers (i.e. C-Reactive)
Time Frame: 6 months
|
plasma concentrations of specific inflammation markers (i.e.
C-Reactive)
|
6 months
|
Weight
Time Frame: 6 months
|
Body weight for infants up to 24 months old
|
6 months
|
Serum concentrations of specific micronutrient status
Time Frame: 6 Months
|
Serum concentrations of specific micronutrient status indices, such as vitamins, minerals and trace elements.
|
6 Months
|
Parameters of cognitive development
Time Frame: 6 Months
|
Parameters of cognitive development such as Memory tests, attention tests,using screening version of the Bayley III Test for Children
|
6 Months
|
Recumbent length
Time Frame: 6 months
|
Length in meters and standing height for toddlers from 24 to 36 months old
|
6 months
|
Plasma concentrations of specific micronutrient status
Time Frame: 6 months
|
Plasma concentrations of specific micronutrient status indices, such as vitamins, minerals and trace elements.
|
6 months
|
Urine concentrations of specific micronutrient status
Time Frame: 6 Months
|
Urine concentrations of specific micronutrient status indices, such as vitamins, minerals and trace elements.
|
6 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intestinal microbiome
Time Frame: 6 months
|
intestinal microbiome in a subpopulation of infants to explore the effect of 2-7 mg of Fe per day (provided as ferrous-sulfate) on the numbers of and changes in Enterobacteriaceae
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Idowu O Senbanjo, MBBS, Lagos State University College of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-GAGA-GND
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Enterobacteriaceae Infections
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCarbapenemase-producing Enterobacteriaceae Infections
-
University Hospital, Strasbourg, FranceRecruitingCarbapenemase-Producing EnterobacteriaceaeFrance
-
Tan Tock Seng HospitalSingapore Clinical Research InstituteNot yet recruitingCarbapenem-Resistant Enterobacteriaceae Infection
-
Qianfoshan HospitalRecruitingCarbapenem-Resistant Enterobacteriaceae InfectionChina
-
Rambam Health Care CampusCompletedCarbapenem-Resistant Enterobacteriaceae InfectionIsrael
-
Rambam Health Care CampusCompletedCarbapenem-Resistant Enterobacteriaceae InfectionIsrael
-
University Hospital, AngersUnknownESBL-producing Enterobacteriaceae Infections
-
The University of Hong KongNot yet recruitingFecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae (FMT)Fecal Microbiota Transplantation | Carbapenem-Resistant Enterobacteriaceae Infection
-
University Hospital, Clermont-FerrandUniversity Hospital, Estaing; Hopital Gabriel MontpiedUnknownAntibiotic Resistance | Extended-spectrum Betalactamase | Enterobacteriaceae | Escherichia ColiFrance
Clinical Trials on Fortified milk Powder
-
Instituto de Desarrollo e Investigaciones Pediátricas...Not yet recruitingInfants | Lactating Mothers
-
GlaxoSmithKlineCompleted
-
Indonesia UniversityBASFRecruitingBody Weight | Overweight and ObesityIndonesia
-
Gadjah Mada UniversityUnknown
-
Hospices Civils de LyonCompletedCardiometabolic RiskFrance
-
Société des Produits Nestlé (SPN)CompletedNutritional Status | Child Nutrition Sciences | ToddlersPhilippines
-
NestléCompletedGrowth | Learning | ToddlersPhilippines
-
Instituto Nacional de Salud Publica, MexicoMead Johnson NutritionCompletedUndernutritionMexico
-
National Center for Research Resources (NCRR)Baylor College of MedicineCompletedSepsis | Necrotizing EnterocolitisUnited States